Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination


CDC researchers have developed recombinant lyssaviruses that can be used for the development of an improved, broad-spectrum vaccine against several rabies genotypes. Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. Currently, there are commercially available vaccines that are considered to be effective against infections from a single viral phylogroup; however, these vaccines confer little or no protection against viruses outside of the phylogroup. The present recombinants have glycoprotein-encoding genes from at least two different lyssaviruses and can be used as pan-lyssaviral vaccines to provide protection against infection by multiple lyssavirus phylogroups.

Potential Commercial Applications: Competitive Advantages:
  • Pan-lyssavirus vaccines
  • Rabies surveillance and vaccination programs
 
  • Broad-spectrum vaccine potential
  • Pan-lyssavirus vaccination tools will be particularly beneficial in endemic and developing regions
  • Employs a presently commercialized vaccine backbone/platform, making this innovation easily adaptable for industrial R&D and subsequent large-scale production


Development Stage:
Pre-clinical

Related Invention(s):
E-326-2013/0


Inventors:

Xianfu Wu (CDC)  ➽ more inventions...

Charles Rupprecht (CDC)  ➽ more inventions...

Ivan Kuzmin (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,248,179 issued 2016-02-02
US Application No. 61/358,288
PCT Application No. PCT/US2011/041579
US Application No. 13/806,622

Publications:
Kuzmin IV, et al. PMID 18514350

Licensing Contact:
Tara Kirby, Ph.D.
Email: tara.kirby@nih.gov
Phone: 240-669-5128

OTT Reference No: E-256-2013/0
Updated: Sep 17, 2013